7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-09-30 2017-06-30 2017-03-31 2016-03-31 
      
    		                                   
      operating activities
    		                                   
      net income
    		17,306,000 -24,420,000 -21,686,000 14,739,000 -6,729,000 -15,697,000 -48,419,000 -33,843,000 -21,577,000 -43,232,000 -52,932,000 -55,865,000 -33,286,000 -62,157,000 -85,260,000 -83,277,000 -50,294,000 -51,225,000 -65,664,000 -71,401,000 -64,011,000 -52,492,000 -88,948,000 -89,729,000 -61,809,000 -84,551,000 -120,299,000 -78,081,000 -159,163,000 -61,835,000 -49,916,000 -111,665,000 -48,137,000 -54,992,000 -43,691,000 
      adjustments to reconcile net income to net cash from operating activities:
    		                                   
      amortization of debt discount and deferred financing
    		658,000 630,000 606,000 597,000 574,000 560,000 531,000 536,000 721,000 692,000 667,000 671,000 668,000 658,000 637,000 638,000 652,000 645,000 555,000 670,000 592,000 301,000 231,000 256,000 186,000 455,000 1,649,000 3,108,000 2,595,000 2,672,000 2,601,000     
      depreciation and amortization
    		1,874,000 1,852,000 1,837,000 2,041,000 2,170,000 2,182,000 2,154,000 2,182,000 2,228,000 2,206,000 1,257,000 1,311,000 1,286,000 1,334,000 1,411,000 1,518,000 1,520,000 1,567,000 1,604,000 2,547,000 2,496,000 2,039,000 1,764,000 1,514,000 1,116,000 1,154,000 991,000         
      stock-based compensation
    		18,089,000 17,559,000 25,172,000 19,217,000 18,688,000 16,197,000 30,803,000 18,095,000 16,511,000 16,577,000 34,894,000  14,772,000 12,463,000 30,651,000 13,907,000 11,841,000 11,736,000 20,354,000 12,239,000 15,908,000 8,408,000 12,596,000 12,908,000 8,843,000 9,935,000 12,744,000 8,387,000 7,054,000 6,341,000 7,478,000 5,500,000 5,537,000 6,030,000 4,283,000 
      foreign currency remeasurement loss
    		   1,067,000 5,776,000 7,655,000 1,736,000 1,492,000 -5,783,000 18,019,000 5,885,000 3,293,000 2,475,000 -320,000 673,000   389,000 2,846,000 6,555,000 -6,688,000 -5,058,000 10,662,000  2,135,000           
      other
    		-835,000 2,794,000 1,175,000  528,000 702,000 5,818,000                 -13,000            
      changes in operating assets and liabilities:
    		                                   
      accounts receivable
    		-8,084,000 -12,492,000 15,330,000 -10,394,000 -8,643,000 -10,004,000 9,557,000 -11,494,000 -11,319,000 4,072,000 -1,367,000 -9,904,000 -3,002,000 -3,424,000 -1,000,000 -1,817,000 -3,245,000 -3,966,000 839,000 -374,000 -457,000 -2,030,000 -8,358,000 1,530,000 -5,815,000 -5,828,000 -1,001,000 -8,112,000 861,000       
      inventories
    		-36,322,000 -22,577,000 -8,288,000 -12,020,000 -34,731,000 -25,223,000 -1,678,000 -2,381,000 -14,750,000 -24,325,000 -3,158,000 -10,256,000 1,376,000 1,725,000 1,812,000 -4,768,000 1,423,000 -5,186,000 741,000 -6,821,000 831,000 1,602,000 -251,000 -3,098,000 -108,000 -2,253,000 345,000 -2,156,000 1,400,000       
      prepaid expenses and other current assets
    		7,570,000 -4,754,000 -3,603,000 -14,255,000 14,257,000 19,299,000 -5,340,000 17,948,000 -13,747,000 -14,102,000 1,839,000 -611,000 -1,102,000 -7,813,000 3,332,000 -14,999,000 3,815,000 -2,404,000 7,669,000 -13,143,000 3,002,000 -2,641,000 4,016,000 34,000 202,000 -6,582,000 3,059,000 -145,000 -1,951,000 -6,291,000 10,875,000     
      accounts payable, accrued expenses, and other current liabilities
    		30,627,000 10,360,000 3,647,000 -5,037,000 -14,124,000 27,124,000 -24,483,000 8,094,000 9,481,000 31,692,000 -72,000 -31,842,000 2,794,000 37,234,000 -14,563,000                     
      other non-current assets and liabilities
    		-3,676,000 411,000 -1,076,000 -2,033,000 -737,000 -104,000 -374,000 1,939,000 -2,407,000 -2,192,000 -394,000 1,306,000 -3,180,000 -1,326,000 -1,436,000 -447,000 -386,000 -206,000 -1,578,000 6,684,000 -1,233,000 4,303,000 -5,334,000 -12,081,000 2,783,000 2,688,000 -3,507,000         
      net cash from operating activities
    		35,660,000 -26,526,000 7,758,000 -3,916,000 -22,971,000 22,691,000 -29,695,000 3,458,000 -38,347,000 -16,133,000 -18,069,000 -80,772,000 -11,626,000 -15,862,000 -58,315,000 -70,514,000 -23,700,000 -35,923,000 -72,354,000 -49,822,000 -42,008,000 -33,518,000 -107,942,000 -57,832,000 -55,553,000 -58,485,000 -78,546,000 -60,677,000 -132,762,000 -56,995,000 -49,521,000     
      investing activities
    		                                   
      sale and redemption of marketable securities
    		17,256,000 10,995,000 6,161,000 15,904,000 39,540,000 23,428,000 38,907,000 16,399,000 53,980,000 71,904,000 54,944,000 76,006,000 75,859,000 75,733,000 108,328,000 81,700,000 83,576,000 95,087,000 163,680,000 82,147,000 62,540,000 103,999,000 106,140,000 109,805,000 127,817,000 126,238,000 135,187,000 75,367,000 177,896,000 89,013,000 121,226,000 93,072,000 68,466,000 69,443,000 53,157,000 
      purchases of marketable securities
    		-18,173,000 -14,370,000 -38,810,000 -36,008,000 -4,912,000 -44,307,000 -29,559,000 -38,625,000 -16,650,000 -19,701,000 -16,747,000 -143,444,000 -1,481,000 -49,086,000 -49,244,000 -148,029,000 -48,114,000 -69,008,000 -76,247,000 -103,856,000 -216,317,000 -32,917,000 -12,088,000 -71,917,000 -120,647,000 -139,140,000 -52,178,000 -137,431,000 -60,729,000       
      capital expenditures
    		-382,000 -2,403,000 -212,000 -288,000 -356,000 -1,098,000 -1,811,000 -1,731,000 -1,565,000 -2,202,000 -1,942,000 -2,677,000 137,000 -355,000 -871,000 -1,760,000 -890,000 -366,000 -868,000 -1,067,000 -284,000 -1,070,000 -806,000 -10,925,000 -3,977,000 -2,166,000 -2,944,000 -1,737,000 -2,690,000       
      free cash flows
    		35,278,000 -28,929,000 7,546,000 -4,204,000 -23,327,000 21,593,000 -31,506,000 1,727,000 -39,912,000 -18,335,000 -20,011,000 -83,449,000 -11,489,000 -16,217,000 -59,186,000 -72,274,000 -24,590,000 -36,289,000 -73,222,000 -50,889,000 -42,292,000 -34,588,000 -108,748,000 -68,757,000 -59,530,000 -60,651,000 -81,490,000 -62,414,000 -135,452,000       
      net cash from investing activities
    		-1,299,000 -5,778,000 -32,861,000 -20,392,000 34,272,000 -21,977,000 7,537,000 -23,957,000 35,765,000 50,001,000 36,255,000 -66,704,000 74,515,000 26,292,000 58,213,000 -68,089,000 34,572,000 25,713,000 86,565,000 -22,776,000 -154,061,000 70,012,000 93,246,000 26,963,000 3,193,000 -15,068,000 80,065,000 -63,801,000 114,477,000 10,727,000 -182,603,000     
      financing activities
    		                                   
      payment of finance leases
    		-17,000 -8,000 -15,000 -43,000 24,000 -36,000 -42,000 -193,000 -31,000 -23,000 -28,000 -191,000 -51,000 -21,000 -20,000 -19,000 -71,000 -21,000 -368,000 -18,000 -20,000 -17,000 -21,000 -243,000 -79,000 -23,000 -75,000         
      withholding taxes paid on vested restricted stock units
    		-1,641,000 -432,000 -11,790,000 -828,000 -2,792,000 -1,684,000 -16,721,000 -1,565,000 -2,347,000                           
      proceeds from stock options exercised
    		339,000 40,000 105,000 1,555,000 1,805,000 863,000 3,454,000 2,414,000 3,442,000 1,750,000 2,655,000 1,119,000 1,333,000 999,000 859,000 1,871,000 1,696,000                   
      proceeds from the issuance of shares in connection with at-the-market offering, net of issuance costs
    		   413,000    0 36,555,000 24,199,000 2,354,000                         
      net cash from financing activities
    		-1,319,000 -400,000 -11,700,000 1,097,000 18,190,000 -857,000 -13,309,000 8,210,000 37,619,000 23,673,000 -7,825,000 557,000 -559,000 693,000 -8,154,000 -104,000 201,113,000 2,235,000 8,829,000 21,548,000 238,711,000 4,086,000 -1,487,000 3,191,000 523,000 196,404,000 17,384,000 359,000 146,804,000 7,033,000 296,579,000     
      effect of exchange rate changes on cash, cash equivalents, and restricted cash
    		-1,200,000 9,987,000 4,819,000 3,107,000 -5,028,000 -294,000 -1,816,000 -3,906,000 16,902,000 -8,191,000 1,507,000 18,501,000 -20,658,000 -9,085,000 -3,377,000 -908,000 -2,702,000 -286,000 -1,153,000 3,785,000 3,521,000 789,000 -4,265,000 4,320,000 -1,650,000           
      net decrease in cash, cash equivalents, and restricted cash at the end of the period
    		31,842,000 -22,717,000 -31,984,000                                 
      cash, cash equivalents, and restricted cash at the beginning of period
    		0 0 216,716,000  0 0 250,077,000  0 0 153,115,000  0 0 249,456,000                     
      cash, cash equivalents, and restricted cash at the end of period
    		31,842,000 -22,717,000 184,732,000  24,463,000 -437,000 212,794,000  51,939,000 49,350,000 164,983,000  41,672,000 2,038,000 237,823,000  209,283,000 -8,261,000 188,049,000  46,163,000 41,369,000 125,893,000             
      supplemental disclosures of cash flow information
    		                                   
      cash paid during the period for interest
    		11,058,000 10,942,000 10,852,000  23,797,000 11,989,000 11,801,000  12,293,000 11,794,000 11,361,000  8,950,000 7,599,000 7,509,000  7,679,000 7,596,000 7,513,000  6,003,000 7,016,000 3,693,000  3,843,000 4,456,000 4,846,000 3,713,000 13,000 3,762,000 12,000 12,000 3,638,000 12,000  
      cash paid for taxes
    		1,614,000 354,000 377,000  1,603,000 491,000 635,000  495,000 5,800,000 178,000  225,000 254,000 456,000  5,328,000 2,054,000 2,472,000                 
      supplemental disclosure of non-cash investing and financing activities
    		                                   
      tenant improvements paid through lease incentives
    		97,000 98,000 97,000  97,000 68,000 52,000          0    15,000 201,000 254,000             
      capital expenditures unpaid at the end of period
    		 36,000 138,000  78,000 -1,020,000 1,110,000  580,000 -963,000 1,260,000  0 -19,000 72,000  136,000 3,000 188,000  -237,000 -87,000 589,000             
      cashless exercise of warrants
    		0 0 71,000                                 
      foreign currency remeasurement (gain) loss
    		 4,111,000 -5,356,000                        325,000         
      loss on extinguishment of debt
    		               0    0                
      non-cash changes in the fair value of contingent consideration payable
    		       0 1,995,000 337,000 251,000 1,584,000 567,000 115,000 -1,188,000 1,734,000 3,288,000 1,021,000 471,000 464,000 1,034,000 715,000 931,000 645,000 789,000 480,000 1,383,000 600,000 1,300,000 300,000 1,100,000  1,050,000 4,578,000 3,152,000 
      non-cash deferred taxes
    		                                49,000 49,000  
      asset impairment charges and other asset write-offs
    		       367,000 300,000   906,000 5,006,000                       
      payment of contingent consideration
    		       -13,410,000 0                           
      proceeds from sale of assets
    		                                   
      proceeds from equity financing, net of issuance costs
    		                                   
      proceeds from warrants exercised
    		       0 0       0 0                   
      payment of long-term debt
    		                   0                
      proceeds from long-term debt, net of issuance costs
    		                   0                
      net increase in cash, cash equivalents, and restricted cash
    		                       -23,358,000 -53,487,000           
      cash, cash equivalents, and restricted cash at the beginning of the year
    		                                   
      cash, cash equivalents, and restricted cash at the end of the year
    		                                   
      deferred taxes
    		        0 0 -4,939,000                         
      net increase in cash, cash equivalents, and restricted cash at the end of the period
    		    24,463,000 -437,000 -37,283,000  51,939,000 49,350,000 11,868,000  41,672,000 2,038,000 -11,633,000  209,283,000    46,163,000 41,369,000 -20,448,000             
      purchase of vested restricted stock units, net of taxes
    		          -12,806,000 -371,000 -1,841,000 -285,000 -8,993,000                     
      share-based compensation
    		                                   
      proceeds from issuance of common stock from equity financing and pre-funded warrants, net of issuance costs
    		                                   
      loss on impairment of assets
    		              6,616,000                     
      loss on exchange of convertible notes
    		                                   
      deferred reimbursements
    		                   0    -4,000,000 0 0 -1,500,000         
      proceeds from issuance of common stock, net of issuance costs
    		                        0    0 0 294,584,000     
      payments of employee withholding taxes related to restricted stock unit vesting
    		               -309,000 -262,000                   
      proceeds from termination of capped call confirmations
    		                       0 0 5,243,000 14,632,000         
      foreign currency remeasurement gain
    		                                   
      accounts payable and accrued expenses
    		                6,417,000 11,706,000 -40,191,000  492,000 11,335,000 -35,251,000  -3,739,000 21,311,000 -8,858,000         
      proceeds from issuance of common stock from equity financing and pre-funded warrants
    		                                   
      cash, cash equivalents, and restricted cash at beginning of period
    		                0 0 166,162,000  0 0 146,341,000  0           
      purchase of vested restricted stock units
    		                  -14,194,000 -688,000 -1,243,000 -554,000 -7,543,000 -234,000 -446,000 -617,000 -1,938,000 -151,000 -654,000       
      proceeds from exercise of stock options
    		                  4,161,000 22,254,000 9,294,000 4,657,000 6,077,000 3,668,000 1,048,000 2,807,000 3,953,000 652,000 912,000 3,602,000 3,978,000 7,287,000 1,289,000 265,000 155,000 
      proceeds from exercise of warrants
    		                  19,230,000         0        
      net increase(decrease) in cash, cash equivalents, and restricted cash at the end of the period
    		                  21,887,000                 
      change in fair value of derivatives
    		                           0 0       
      loss on exchange of convertible debt
    		                       0 0 4,501,000 36,123,000         
      proceeds of exercise of warrants
    		                        0 0 812,000         
      contingent consideration paid in shares
    		                                   
      loss on impairment
    		                                   
      proceeds from issuance of common stock and warrants, net of issuance costs
    		                                   
      proceeds from loan agreements, net of issuance costs
    		                                   
      proceeds from senior secured term loan
    		                                   
      cash, cash equivalents, and restricted cash at end of period
    		                        -53,487,000           
      capital expenditures, unpaid
    		                        1,965,000      142,000     
      payment of contingent consideration in shares
    		                        0 0 9,316,000         
      capital expenditures funded by capital lease
    		                            -1,000       
      effect of exchange rate changes on cash, cash equivalents and restricted cash
    		                          -2,350,000 2,664,000 -130,000       
      net decrease in cash, cash equivalents and restricted cash
    		                          16,553,000         
      cash, cash equivalents and restricted cash at beginning of period
    		                          82,375,000         
      cash, cash equivalents and restricted cash at end of period
    		                          98,928,000         
      depreciation
    		                           1,201,000 1,073,000 973,000 969,000 850,000 813,000 823,000 673,000 
      restructuring charges
    		                                  50,000 
      charges to research expense for stock issued in asset acquisition
    		                                   
      (gain) loss on disposal of assets
    		                                   
      other non-current assets
    		                           62,000 -308,000       
      account payable and accrued expenses
    		                           13,431,000 15,485,000       
      non-current liabilities
    		                           -223,000 224,000 237,000 220,000 141,000 133,000 363,000 380,000 
      payments of secured loan agreement
    		                                   
      payment of capital leases
    		                           -116,000 -76,000       
      proceeds from issuance of convertible notes, net of issuance costs
    		                                   
      premiums paid for capped call confirmations
    		                                   
      net increase in cash and cash equivalents and restricted cash
    		                           -121,455,000 128,389,000 -41,111,000 65,315,000     
      cash and cash equivalents and restricted cash at beginning of year/period
    		                                   
      cash and cash equivalents and restricted cash at end of year/period
    		                                   
      capital expenditures funded by capital lease borrowings
    		                                   
      gain on disposal of asset
    		                                   
      foreign currency remeasurement (gain)/ loss
    		                            -1,332,000       
      deferred reimbursement
    		                            0       
      proceeds from senior secured term loan, net of issuance costs
    		                                   
      payment of deferred financing fees
    		                                   
      cash and cash equivalents and restricted cash at beginning of period
    		                            0 0 51,237,000     
      cash and cash equivalents and restricted cash at end of period
    		                            128,389,000 -41,111,000 116,552,000     
      effect of exchange rate changes on cash and cash equivalents and restricted cash
    		                              860,000     
      (gain)/ loss on disposal of asset
    		                                   
      change in fair value of derivative liability
    		                                   
      non-cash deferred taxes and other tax benefits
    		                                   
      purchases of property and equipment
    		                                   
      proceeds from unsecured loan agreement
    		                                   
      effect of exchange rate changes on cash and cash equivalents
    		                               416,000 534,000 80,000  
      net decrease in cash and cash equivalents
    		                                   
      cash and cash equivalents at beginning of year/ period
    		                               0 0 187,026,000  
      cash and cash equivalents at end of year/period
    		                               26,739,000 -7,361,000 44,755,000  
      contingent consideration resolution in shares
    		                                   
      non-cash interest expense
    		                                2,312,000 2,403,000 451,000 
      non-cash income tax benefit
    		                                   
      net cash used in/ (provided by) financing activities
    		                                   
      capital expenditures unpaid at end of the period
    		                                   
      loss on disposal of asset
    		                                   
      non-cash changes in the fair value of derivative liability
    		                                   
      acquisitions, net cash of acquired
    		                                   
      proceeds from unsecured note agreement
    		                                   
      proceeds from related party
    		                                   
      payment of capital lease
    		                                   
      cash and cash equivalents at beginning of period
    		                                  69,485,000 
      cash and cash equivalents at end of period
    		                                  23,510,000 
      net cash (used in)/ provided by investing activities
    		                                   
      net (decrease)/ increase in cash and cash equivalents
    		                                   
      net cash (used in)/ provided by financing activities
    		                                   
      receivable due from collaboration agreements
    		                                   
      net cash (used in) investing activities
    		                                   
      net increase/(decrease) in cash and cash equivalents
    		                                   
      net cash provided by/(used in) investing activities
    		                                   
      net cash provided by/(used in) financing activities
    		                                   
      change in fair value of warrant liability
    		                                   
      net cash (used in)/provided by financing activities
    		                                   
      non-cash activities
    		                                   
      amortization of non-cash compensation
    		                                   
      non-cash charge for stock based compensation issued to consultants
    		                                   
      stock-based license payments
    		                                   
      impairment of leasehold improvements
    		                                   
      non-cash charge for in-process research and development
    		                                   
      beneficial conversion feature related to bridge financing
    		                                   
      receivable due from gsk
    		                                   
      proceeds from the issuance of preferred stock, net of issuance costs
    		                                   
      proceeds from the issuance of common stock and warrants, net of issuance costs
    		                                   
      proceeds from the issuance of convertible notes
    		                                   
      payments of capital lease obligations
    		                                   
      payments related to deferred financing
    		                                   
      proceeds from capital asset financing arrangement
    		                                   
      proceeds from secured loan agreement
    		                                   
      net (decrease)/increase in cash and cash equivalents
    		                                   
      stock-based compensation - employees
    		                                   
      stock-based compensation - non-employees
    		                                   
      redemption of marketable securities
    		                                   
      proceeds from secured loan arrangement
    		                                   
      net cash provided by/ (used in) financing activities
    		                                   
      receivable from gsk
    		                                   
      net cash (used in)/provided by investing activities
    		                                   
      deferred revenue
    		                                   
      stock-based license payment
    		                                   
      non-cash charge for in process research and development
    		                                   
      conversion of preferred stock to common stock
    		                                   
      conversion of notes payable to series b redeemable convertible preferred stock
    		                                   
      accretion of redeemable convertible preferred stock
    		                                   
      beneficial conversion feature related to issuance of the additional issuance of series c redeemable convertible preferred stock
    		                                   
      stock-based compensation — employees
    		                                   
      stock-based compensation — non-employees
    		                                   
      debt instrument convertible beneficial conversion feature
    		                                   
      adjustments to reconcile net income to net cash (used in)/provided by operating activities:
    		                                   
      net cash provided by/(used in) operating activities
    		                                   
      proceeds from the issuance of common stock, net of issuance costs
    		                                   
      conversion of notes payable to preferred stock
    		                                   
      beneficial conversion feature related to the issuance of series c redeemable convertible preferred stock
    		                                   
      net increase in cash and cash equivalents
    		                                   
      beneficial conversion feature related to issuance of the second tranche of series c redeemable convertible preferred stock
    		                                   
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.